TARS · Tarsus Pharmaceuticals
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $65
Note written ·
How this view changed
- · Rated Medium. Results, 3 November 2026: Tarsus reported Q3 2026 XDEMVY net product sales of $194.6 million, above Q2's $173.9 million, and raised 2026 sales guidance to $715–730 million from $685–705 million.
Price against the kill line
23.5% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $65.00, on record since 10 November 2026. The shares are up 13.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $65, under the October trading range that held near $70–72. A fourth-quarter 2026 XDEMVY sales miss against the raised $715–730 million guidance, or a new equity raise to fund the pipeline, would also break the case.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 3 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 195
- Revenue, change on a year (%)
- +63.9
- Gross margin (%)
- 92.9
- Operating margin (%)
- −340.3
- Free cash flow, four quarters ($M)
- 32.4
- Net cash, cash less debt ($M)
- 237
- Enterprise value to sales (×)
- 5.5
- Free-cash-flow yield (%)
- 0.8
All filed numbers
What Tarsus Pharmaceuticals reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 195 | +63.9 | 92.9 | −340.3 |
| first filed | 174 | +69.4 | 93.0 | −11.4 |
| first filed | 162 | +106.9 | 94.2 | −3.8 |
| first filed | 152 | +128.4 | — | −5.3 |
| first filed | 119 | +146.7 | 93.0 | −12.2 |
| first filed | 103 | +151.5 | 93.9 | −21.6 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −702 | −668 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +9.0 |
| Operating cash flow ($M) | 49.9 |
| Capital spending ($M) | 17.5 |
| Free cash flow ($M) | 32.4 |
| Cash and short-term investments ($M) | 310 |
| Debt ($M) long-term debt | 72.9 |
| Net cash, cash less debt ($M) | 237 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 100 |
| Inventory ($M) | 5.2 |
| Shareholders' equity ($M) | 104 |
| Market value ($M) | 3,958 |
| Enterprise value, market value plus net debt ($M) | 3,722 |
| Enterprise value to sales (×) | 5.5 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 38.0 |
| Free-cash-flow yield (%) | 0.8 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 11.6% of shares outstanding sold short, 5.7 days of average trading to cover, −5.6% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $5.2M |
| 12 monthsfrom | $0 | $20.0M |
The thesis
Tarsus Pharmaceuticals' case is intact: XDEMVY, its treatment for eyelid mite infestation (Demodex blepharitis), beat the prior quarter and the company raised 2026 guidance. Third-quarter 2026 net product sales were $194.6 million, against $173.9 million in the second quarter, and guidance rose to $715–730 million from $685–705 million. The fourth-quarter report and the first-half 2027 pipeline readouts settle whether that funds the Alkeus retina program.
The shares have not moved with the news. The adjusted close was $70.84 on 9 November 2026, against $70.76 on 27 October 2026, and is 22.0% below the 52-week high of $90.78. The 3-month price change is 1.2% and the 14-day relative strength index (RSI, a 0–100 momentum gauge) reads 49.6.
The story is well known: the launch is well known, four firms raised targets between 4 November 2026 and 5 November 2026, and the shares did not respond. Growth is slowing (85% year over year in the first quarter, more than 69% in the second, about 64% in the third), and cash fell to $309.6 million at 30 September 2026 from $449.7 million at 30 June 2026.
Bullish and bearish views on Tarsus Pharmaceuticals, Inc.
The bull case on Tarsus Pharmaceuticals, Inc. (TARS), in brief: sales beat and guidance raised. The bear case: growth is decelerating.
Bull case
- Sales beat and guidance raised. Third-quarter XDEMVY net product sales were $194.6 million, up about 64% from $118.7 million a year earlier. Full-year guidance moved to $715–730 million per Vision Monday. Earnings Whispers calculates that range implies fourth-quarter sales of roughly $201–216 million. Q3 2026 release
- Prescriber base is widening. Vision Monday reports that eye-care professionals prescribing at least five bottles a week rose 20% from the second quarter. About 20% of weekly prescriptions are refills.
- Analyst targets sit far above the price. On 4 November 2026 HC Wainwright raised its target to $106 and Oppenheimer to $103. On 5 November 2026 Mizuho raised to $102 and Guggenheim to $97. Goldman Sachs ($116) and Barclays ($110) published higher targets in September. The $70.84 close on 9 November 2026 is below all of them.
- Pipeline data arrive within months. The Q3 release guides TP-04 (ocular rosacea) and TP-05 (Lyme disease prevention) topline data to the first half of 2027. TP-05 enrollment is complete.
Bear case
- Growth is decelerating. Year-over-year sales growth was 85% in the first quarter, more than 69% in the second and about 64% in the third, per company releases dated May 2026 to 3 November 2026. The raised guidance still leaves a compounding comparison to clear.
- Spending outpaces sales. Third-quarter SG&A was $168.0 million, up from $108.6 million, and R&D was $44.2 million, up from $16.3 million. Year-to-date SG&A is $455.1 million.
- Cash is lower and a raise is possible. Cash, equivalents and marketable securities were $309.6 million at 30 September 2026. Long-term debt, net was $72.9 million, and non-current contingent consideration for the Alkeus regulatory milestone was $85.7 million. The release announces no new financing.
- Share supply is registered. A prospectus filed 13 October 2026 covers resale of up to 2.91 million shares by selling stockholders, and $180 million of the $450 million Alkeus upfront was paid in Tarsus stock.
- One product carries all revenue. XDEMVY was all $194.6 million of third-quarter net product sales. The net loss was $668.3 million, mostly from $632.2 million of acquired in-process R&D.
Price setup
Adjusted daily closes put the shares at $70.84 on 9 November 2026. That sits near the $70.76 close of 27 October 2026 and below the $72.29 close of 14 October 2026. The shares were roughly flat through a sales beat, a guidance raise and four target increases, which shows buyers have not yet paid for the raised outlook.
The 52-week high is $90.78, 22.0% above the last close. An RSI of 49.6 is neutral. The $65 level in the kill line is about 8% below the last close and under the range of the past month.
Crowding evidence is limited. Analyst targets are uniformly above the price, but the earnings date has passed and the October resale registrations are the main visible supply. The company announced investor conference participation on 5 November 2026 and appointed Neera Clase as Chief Commercial Officer on 28 October 2026.
Catalysts ahead
- ~February 2027 (est.): Fourth-quarter and full-year 2026 report, date unconfirmed. Tests whether Q4 sales reach the $201–216 million that Earnings Whispers calculates the new guidance implies.
- 2027 first half: Topline data for TP-04 (ocular rosacea) and TP-05 (Lyme disease prevention). The first readouts that could show XDEMVY's maker can expand beyond one product.
Elapsed catalysts
- 5 November 2026 (announced): Tarsus announced participation in upcoming investor conferences (dates in the company's 5 November 2026 release). Management commentary on prescription trends, refills and spending after the guidance raise; no financial figures are scheduled. (passed)
What would change the view
A daily close below $65, under the October trading range that held near $70–72. A fourth-quarter 2026 XDEMVY sales miss against the raised $715–730 million guidance, or a new equity raise to fund the pipeline, would also break the case.
The risks this note tracks, each with what would confirm it:
- XDEMVY growth keeps slowing while spending rises, extending losses and drawing down cash. Confirmed by: fourth-quarter 2026 sales below the low end of the implied range, or year-over-year growth falling below the 64% reported for Q3.
- Cash of $309.6 million at 30 September 2026 leads to another equity raise or stock-funded deal. Confirmed by: a new offering announcement, or further acquisitions paid in stock, before the 2027 TP-04 and TP-05 readouts.
- Share supply from the October 2026 resale registrations caps the price. Confirmed by: closes falling below the October trading range near $70 while the registered shares are sold.
- The 2027 Phase 2 readouts for TP-04 or TP-05 disappoint. Confirmed by: a missed primary endpoint or a delay beyond the first half of 2027.
What it trades with
Tarsus trades on its own product cycle. XDEMVY prescription data and the company's quarterly sales figures drive the shares more than sector moves. Small and mid-cap biotech indices and the Nasdaq Biotechnology Index set the background for risk appetite, but no measured correlation figure is available for this note. The four target increases on 4 November 2026 and 5 November 2026 did not lift the price, so analyst revisions alone have had little effect.
The evidence, claim by claim (8)
- Q3 2026 XDEMVY net product sales were $194.6 million ($194,569K), up about 64% from $118.7 million in Q3 2025. Tarsus Q3 2026 release, 8-K Exhibit 99.1 · as of
- Full-year 2026 XDEMVY net sales guidance is $715–730 million, raised from $685–705 million. Vision Monday report on Q3 2026 results · as of
- Q3 2026 SG&A was $168.0 million (vs $108.6 million) and R&D $44.2 million (vs $16.3 million). Tarsus Q3 2026 release, 8-K Exhibit 99.1 · as of
- Q3 2026 net loss was $668.3 million, including $632.2 million of acquired in-process R&D ($81.0 million iRenix, $551.2 million Alkeus). Tarsus Q3 2026 release, 8-K Exhibit 99.1 · as of
- Cash, cash equivalents and marketable securities were $309.6 million at 30 September 2026; long-term debt, net was $72.9 million. Tarsus Q3 2026 release, 8-K Exhibit 99.1 · as of
- Topline data for TP-04 (ocular rosacea) and TP-05 (Lyme disease prevention) are expected in the first half of 2027; IRX-101 Phase 3 topline in 2028; gildeuretinol Phase 3 NORTHSTAR topline in 2029. Tarsus Q3 2026 release, 8-K Exhibit 99.1 · as of
- HC Wainwright raised its target to $106 and Oppenheimer to $103 (4 November 2026); Mizuho raised to $102 and Guggenheim to $97 (5 November 2026). Benzinga analyst-action headlines · as of
- Adjusted daily close $70.84, 22.0% below the 52-week high of $90.78; 3-month price change 1.2%; RSI(14) 49.6. Adjusted daily closes · as of
Sources